INT95646

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 2001
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 63
Total Number 63
Disease Relevance 25.61
Pain Relevance 36.78

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (Faah) Golgi apparatus (Faah) endoplasmic reticulum (Faah)
cytoplasm (Faah)
Anatomy Link Frequency
brain 5
forebrain 2
limb 2
plasma 1
tail 1
Faah (Mus musculus)
Pain Link Frequency Relevance Heat
Endocannabinoid 906 100.00 Very High Very High Very High
Cannabinoid 456 100.00 Very High Very High Very High
Pain 340 100.00 Very High Very High Very High
IPN 9 99.92 Very High Very High Very High
Neuropathic pain 231 99.84 Very High Very High Very High
Antinociceptive 107 99.84 Very High Very High Very High
Analgesic 193 99.76 Very High Very High Very High
analgesia 105 99.52 Very High Very High Very High
Inflammation 164 99.30 Very High Very High Very High
cytokine 9 99.30 Very High Very High Very High
Disease Link Frequency Relevance Heat
Inflammatory Pain 80 99.92 Very High Very High Very High
Neuropathic Pain 399 99.84 Very High Very High Very High
Anxiety Disorder 219 99.76 Very High Very High Very High
Pain 386 99.44 Very High Very High Very High
INFLAMMATION 170 99.08 Very High Very High Very High
Depression 350 98.96 Very High Very High Very High
Cancer Pain 6 98.20 Very High Very High Very High
Hyperalgesia 115 97.48 Very High Very High Very High
Injury 125 97.08 Very High Very High Very High
Bone Cancer 10 96.30 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Likewise, pharmacological blockade of FAAH activity reduces nocifensive behavior in animal models of acute and inflammatory pain.
Negative_regulation (blockade) of FAAH associated with eae
1) Confidence 0.59 Published 2007 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 17412883 Disease Relevance 0.40 Pain Relevance 0.50
Oral dosing with URB597 achieved significant, albeit transient, drug levels in plasma, inhibited brain FAAH activity, and elevated spinal cord anandamide content.
Negative_regulation (inhibited) of FAAH in plasma associated with spinal cord
2) Confidence 0.59 Published 2007 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 17412883 Disease Relevance 0.46 Pain Relevance 0.84
N-arachidonoylserotonin (AA-5-HT, 1a) is an inhibitor of fatty acid amide hydrolase (FAAH) that acts also as an antagonist of transient receptor potential vanilloid-type 1 (TRPV1) channels and is analgesic in rodents.
Negative_regulation (inhibitor) of fatty acid amide hydrolase associated with analgesic and antagonist
3) Confidence 0.58 Published 2007 Journal J. Med. Chem. Section Abstract Doc Link 18027904 Disease Relevance 0.07 Pain Relevance 0.32
N-arachidonoylserotonin (AA-5-HT, 1a) is an inhibitor of fatty acid amide hydrolase (FAAH) that acts also as an antagonist of transient receptor potential vanilloid-type 1 (TRPV1) channels and is analgesic in rodents.
Negative_regulation (inhibitor) of FAAH associated with analgesic and antagonist
4) Confidence 0.58 Published 2007 Journal J. Med. Chem. Section Abstract Doc Link 18027904 Disease Relevance 0.07 Pain Relevance 0.32
FAAH inhibition of > or =76% in brain depresses movement of mice administered anandamide at 30 mg/kg ip, often leading to limb recumbency.
Negative_regulation (inhibition) of FAAH in limb
5) Confidence 0.58 Published 2001 Journal Toxicol. Appl. Pharmacol. Section Abstract Doc Link 11350214 Disease Relevance 0.12 Pain Relevance 0.15
Two BDPOs (dodecyl and phenyl) and EOPF are potent inhibitors of FAAH in vivo (ED50 0.5--6 mg/kg).
Negative_regulation (inhibitors) of FAAH
6) Confidence 0.58 Published 2001 Journal Toxicol. Appl. Pharmacol. Section Abstract Doc Link 11350214 Disease Relevance 0.18 Pain Relevance 0.15
In more general terms, these findings suggest that selective inhibitors of FAAH might represent a viable pharmacological approach for the clinical treatment of pain disorders.
Negative_regulation (inhibitors) of FAAH associated with pain
7) Confidence 0.55 Published 2004 Journal Pain Section Abstract Doc Link 15157693 Disease Relevance 1.18 Pain Relevance 0.92
Novel arvanil derivatives prepared by N-methylation, replacement of the amide with urea and thiourea moieties, and manipulation of the vanillyl group were evaluated for their ability to bind/activate CB1 receptors, activate VR1 receptors, inhibit the AMT and fatty acid amide hydrolase (FAAH), and produce cannabimimetic effects in mice.
Negative_regulation (inhibit) of FAAH
8) Confidence 0.54 Published 2002 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 11861807 Disease Relevance 0 Pain Relevance 0.29
On the aromatic ring, the substitution of the 3-methoxy group with a chlorine atom or the lack of the 4-hydroxy group decreased the activity on VR1 and AMT, but not the affinity for CB1 receptors, and increased the capability to inhibit FAAH.
Negative_regulation (inhibit) of FAAH
9) Confidence 0.54 Published 2002 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 11861807 Disease Relevance 0 Pain Relevance 0.23
Methylation of the amide group decreased the activity at VR1, AMT, and FAAH.
Negative_regulation (decreased) of FAAH
10) Confidence 0.47 Published 2002 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 11861807 Disease Relevance 0 Pain Relevance 0.27
Additionally, neither UCM707 [N-(3-furanylmethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide], the inhibitor of the putative anandamide membrane transporter (AMT), nor methyl arachidonoyl fluorophosphonate (MAFP), the inhibitor of fatty acid amidohydrolase (FAAH), were able to affect the inhibitory activity of anandamide upon interleukin-2.
Negative_regulation (inhibitor) of FAAH
11) Confidence 0.46 Published 2004 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 15284281 Disease Relevance 0.14 Pain Relevance 0.14
Despite weak FAAH inhibition, R-flurbiprofen significantly increased anandamide levels in unstimulated and LPS-stimulated microglia in vitro (Fig. 4 a).
Negative_regulation (inhibition) of FAAH in microglia
12) Confidence 0.44 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2869361 Disease Relevance 0.24 Pain Relevance 0.33
Here, we tested WIN 55212-2 [(R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de)-1,4-benzoxazin-6-yl]-1-napthalenylmethanone], a cannabinoid receptor agonist, and genetic deletion or pharmacological inhibition of FAAH in the lipopolysaccharide (LPS) mouse model of inflammatory pain.
Negative_regulation (inhibition) of FAAH associated with cannabinoid receptor, ipn and agonist
13) Confidence 0.43 Published 2010 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 20375198 Disease Relevance 0.75 Pain Relevance 0.90
Cyclohexylcarbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597) is an inhibitor of FAAH, increases brain anandamide levels and enhances anandamide-induced antinociception in male ICR mice (25-30 g).
Negative_regulation (inhibitor) of FAAH in brain associated with antinociception
14) Confidence 0.43 Published 2008 Journal Eur. J. Pharmacol. Section Abstract Doc Link 18762181 Disease Relevance 0 Pain Relevance 0.61
The implications of this model in the study of pain in mice, and the therapeutic potential of FAAH inhibition to provide analgesia without the undesirable side effects of direct agonism of cannabinoid receptors are discussed.
Negative_regulation (inhibition) of FAAH associated with pain, cannabinoid receptor and analgesia
15) Confidence 0.43 Published 2008 Journal Neuroscience Section Abstract Doc Link 18541380 Disease Relevance 0.48 Pain Relevance 0.86
Fatty acid amide hydrolase inhibition enhances the anti-allodynic actions of endocannabinoids in a model of acute pain adapted for the mouse.
Negative_regulation (inhibition) of Fatty acid amide hydrolase associated with endocannabinoid and acute pain
16) Confidence 0.43 Published 2008 Journal Neuroscience Section Title Doc Link 18541380 Disease Relevance 0.61 Pain Relevance 1.08
Fatty acid amide hydrolase inhibition by neurotoxic organophosphorus pesticides.
Negative_regulation (inhibition) of Fatty acid amide hydrolase associated with cannabinoid
17) Confidence 0.43 Published 2001 Journal Toxicol. Appl. Pharmacol. Section Title Doc Link 11350214 Disease Relevance 0.26 Pain Relevance 0.16
More generally, OP compound-induced FAAH inhibition and the associated anandamide accumulation may lead to reduced limb mobility as a secondary neurotoxic effect.
Negative_regulation (inhibition) of FAAH in limb
18) Confidence 0.43 Published 2001 Journal Toxicol. Appl. Pharmacol. Section Abstract Doc Link 11350214 Disease Relevance 0.06 Pain Relevance 0.14
Thus, OP pesticides and related inhibitors of FAAH potentiate the cannabinoid activity of anandamide in mice.
Negative_regulation (inhibitors) of FAAH associated with cannabinoid
19) Confidence 0.43 Published 2001 Journal Toxicol. Appl. Pharmacol. Section Abstract Doc Link 11350214 Disease Relevance 0.06 Pain Relevance 0.15
Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydrolase and cannabinoid CB1 receptors.
Negative_regulation (deficient) of fatty acid amide hydrolase associated with analgesic and cannabinoid
20) Confidence 0.43 Published 2007 Journal Eur. J. Pharmacol. Section Title Doc Link 17217945 Disease Relevance 0.16 Pain Relevance 0.45

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox